{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:13:16Z","timestamp":1791411196073,"version":"4.3.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T00:00:00Z","timestamp":1452729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T00:00:00Z","timestamp":1452729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006399","name":"Spectrum Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s10637-015-0321-8","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T08:58:54Z","timestamp":1452761934000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies"],"prefix":"10.1007","volume":"34","author":[{"given":"Emiliano","family":"Calvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Garc\u00eda-Ca\u00f1amaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Tjornelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Rim","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee F.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,14]]},"reference":[{"issue":"8","key":"321_CR1","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-06-0111","volume":"5","author":"X Qian","year":"2006","unstructured":"Qian X, LaRochelle WJ, Ara G, et al. (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5(8):2086\u20132095","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"321_CR2","first-page":"721","volume":"2","author":"JA Plumb","year":"2003","unstructured":"Plumb JA, Finn PW, Williams RJ, et al. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel deacetylase inhibitor PXD101. Mol Cancer Ther 2(8):721\u2013728","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"321_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769\u2013784","journal-title":"Nat Rev Drug Discov"},{"key":"321_CR4","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, et al. (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33:2492\u20132499","journal-title":"J Clin Oncol"},{"issue":"3","key":"321_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","volume":"14","author":"NL Steele","year":"2008","unstructured":"Steele NL, Plumb JA, Vidal L, et al. (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14(3):804\u2013810","journal-title":"Clin Cancer Res"},{"issue":"1","key":"321_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00003088-200645010-00003","volume":"45","author":"JH Beumer","year":"2006","unstructured":"Beumer JH, Beijnen JH, Schellens JH (2006) Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinetics 45(1):33\u201358","journal-title":"Clin Pharmacokinetics"},{"issue":"4","key":"321_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/bdd.661","volume":"30","author":"N Penner","year":"2009","unstructured":"Penner N, Klunk LJ, Prakash C (2009) Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30(4):185\u2013203","journal-title":"Biopharm Drug Dispos"},{"key":"321_CR8","first-page":"1","volume":"8","author":"LZ Wang","year":"2013","unstructured":"Wang LZ, Ramirez J, Yeo W, et al. (2013) Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One 8:1\u201310","journal-title":"PLoS One"},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpba.2013.03.025","volume":"81-82","author":"BF Kiesel","year":"2013","unstructured":"Kiesel BF, Parise RA, Tjornelund J, et al. (2013) LC-MS\/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. J Pharm Biomed Anal 81-82:89\u201398","journal-title":"J Pharm Biomed Anal"},{"key":"321_CR10","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","volume":"333","author":"PJ Bosma","year":"1995","unstructured":"Bosma PJ, Chowdhury JR, Bakker C, et al. (1995) The genetic basis of reduced expression of bilirubin UDP-glucuronosyltransferase in gilbert\u2019s syndrome. N Engl J Med 333:1171\u20131175","journal-title":"N Engl J Med"},{"key":"321_CR11","doi-asserted-by":"crossref","unstructured":"Goey AK, Sissung TM, Peer CJ et al (2015) Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics and toxicities of belinostat administered by 48\u00a0h continuous infusion in patients with cancer. J Clin Pharmacol (ahead of print).","DOI":"10.1158\/1538-7445.AM2015-5480"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0321-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0321-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:51:47Z","timestamp":1678510307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0321-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,14]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0321-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,14]]},"assertion":[{"value":"18 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Emiliano Calvo, MD, PhD, Valentina Boni, MD, PhD, and Lina Garc\u00eda-Ca\u00f1amaque, MD declare that they have no conflict of interest. Guru Reddy, PhD, Tao Song,\u00a0PhD, Mi Rim Choi, MD, and Lee F. Allen, MD, PhD are employees and stockholders of Spectrum Pharmaceuticals, Inc., and Jette Tjornelund, PhD was an employee and stockholder of Onxeo at the time of study conduct.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}